Federated Hermes (FHI) Stock Price, News & Analysis

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Federated Hermes in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FHI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FHI, but not buy additional shares or sell existing shares.
View FHI analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 12 month target prices for Federated Hermes' stock. Their FHI share price targets range from $32.00 to $44.00. On average, they anticipate the company's share price to reach $38.00 in the next year. This suggests a possible upside of 8.3% from the stock's current price.
View analysts price targets for FHI or view top-rated stocks among Wall Street analysts.

Federated Hermes' stock was trading at $33.86 at the start of the year. Since then, FHI stock has increased by 3.6% and is now trading at $35.08.
View the best growth stocks for 2024 here.

Federated Hermes saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,450,000 shares, an increase of 16.0% from the February 29th total of 1,250,000 shares. Based on an average daily trading volume, of 708,500 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.8% of the company's shares are sold short.
View Federated Hermes' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our FHI earnings forecast.

Federated Hermes will be holding an earnings conference call on Friday, April 26th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "50336".

Federated Hermes, Inc. (NYSE:FHI) issued its earnings results on Friday, January, 26th. The company reported $0.96 earnings per share for the quarter, topping analysts' consensus estimates of $0.84 by $0.12. The firm had revenue of $391.50 million for the quarter, compared to analysts' expectations of $396.97 million. Federated Hermes had a trailing twelve-month return on equity of 26.76% and a net margin of 18.58%. Federated Hermes's quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.90 earnings per share.

Federated Hermes declared a quarterly dividend on Thursday, January 25th. Investors of record on Thursday, February 8th will be paid a dividend of $0.28 per share on Thursday, February 15th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 3.19%. The ex-dividend date of this dividend is Wednesday, February 7th.
Read our dividend analysis for FHI.

Federated Hermes (NYSE:FHI) pays an annual dividend of $1.12 per share and currently has a dividend yield of 3.13%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 32.84%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, FHI will have a dividend payout ratio of 27.25% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for FHI.

ETFs with the largest weight of Federated Hermes (NYSE:FHI) stock in their portfolio include The Acquirers Fund (ZIG), SPDR S&P Capital Markets ETF (KCE), Cambria Shareholder Yield ETF (SYLD), WisdomTree U.S. SmallCap Quality Dividend Growth Fund (DGRS), Gabelli Financial Services Opportunities ETF (GABF) and Royce Quant Small-Cap Quality Value ETF (SQLV).Timothy Plan US Small Cap Core ETF (TPSC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Federated Hermes investors own include AbbVie (ABBV), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Micron Technology (MU), Tesla (TSLA), Allison Transmission (ALSN), Alexion Pharmaceuticals (ALXN), Anthem (ANTM), Arrowhead Pharmaceuticals (ARWR) and Boston Scientific (BSX).

Federated Hermes' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Foundation Resource Management Inc. (0.50%), Murphy Pohlad Asset Management LLC (0.13%), Congress Asset Management Co. MA (0.06%), Radnor Capital Management LLC (0.05%), DGS Capital Management LLC (0.02%) and Janiczek Wealth Management LLC (0.01%). Insiders that own company stock include Dolores D Dudiak, Gordon J Ceresino, J Christopher Donahue, John B Fisher, Meter Stephen Van, Michael J Farrell, Paul A Uhlman, Paul A Uhlman, Peter J Germain, Richard A Novak, Saker Anwar Nusseibeh and Thomas R Donahue.
View institutional ownership trends.

Shares of FHI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.